Overview

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

This study will determine the efficacy of oral risperidone (Risperdal) versus long-acting injectable paliperidone palmitate (Invega Sustenna) in treating people with first-episode schizophrenia.

Phase:

Phase 4

Details

Lead Sponsor:

University of California, Los Angeles

Collaborators:

Janssen Scientific Affairs, LLC
National Institute of Mental Health (NIMH)

Treatments:

Paliperidone Palmitate
Risperidone